NCT04493983 is a NA clinical trial of laparoscopic salpingo-oophorectomy in Oophorectomy, sponsored by Ismet Hortu.

Who is sponsoring NCT04493983?

NCT04493983 is sponsored by Ismet Hortu.

What drugs are being tested in NCT04493983?

Interventions in NCT04493983: laparoscopic salpingo-oophorectomy, Laparoscopic bilateral salpingo-oophorectomy.

What condition does NCT04493983 study?

NCT04493983 studies Oophorectomy, Oxidative Stress, Ischemia Reperfusion Injury.

Is NCT04493983 still recruiting?

NCT04493983 is currently completed. Last updated 25 May 2021.

Last reviewed 2021-05-25 · How we verify

NCT04493983

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Role of Oxidative Stress in Ovarian Tissue After CO2-pneumoperitoneum Application-induced I/R

Completed NA Last updated 25 May 2021

What this trial tests

NA trial testing laparoscopic salpingo-oophorectomy in Oophorectomy in 30 participants. Completed in 1 September 2020.

Timeline

1 September 2019

Primary endpoint
1 September 2020

1 September 2020

Quick facts

Lead sponsor	Ismet Hortu
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	30
Start date	1 September 2019
Primary completion	1 September 2020
Estimated completion	1 September 2020
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

laparoscopic salpingo-oophorectomy
Laparoscopic bilateral salpingo-oophorectomy

Conditions studied

Oophorectomy — all drugs for Oophorectomy →
Oxidative Stress — all drugs for Oxidative Stress →
Ischemia Reperfusion Injury — all drugs for Ischemia Reperfusion Injury →

Sponsor

Ismet Hortu

Who can join

Adults 18 to 40, female only, with Oophorectomy or Oxidative Stress. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Because of cellular changes in response to ischemia and a following period of reperfusion, damages to organs and different tissues occur. There are several ongoing studies to enlighten the pathophysiological processes underlying these damages inflicted by ischemia/reperfusion. Gases (CO2) with low water content are used in pneumoperitoneum, which is a procedure to inflate the abdominal cavity with an appropriate gas for laparoscopic operations. In the current literature, it was shown that due to a restricted blood flow during the gas insufflation, ischemia develops and with the reperfusion of the organ in deflation period, oxidative stress and inflammation increases, leading to ischemia/reperfusion-related organ and tissue damages. In the proposed study, biomarkers for ischemia/reperfusion-inflicted damage will be evaluated in a biochemical and histopathological perspective in biopsy samples of ovaries from a young patient group in which hysterectomy and bilateral salpingo-oophorectomy will be performed, laparoscopically.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04493983 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ismet Hortu
Last refreshed: 25 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04493983.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing